Subscribe to RSS
DOI: 10.1055/a-2238-4842
Stammzelltherapie bei Pyoderma gangraenosum
Stem cell therapy for pyoderma gangrenosum
Zusammenfassung
Das Pyoderma gangraenosum ist ein seltene autoinflammatorische [1] neutrophilenreiche Dermatitis/Pannikulitis. Wir stellen eine 59-jährige Patientin vor, die an einem Mammakarzinom behandelt wurde und nachfolgend einen ausgedehnten Hautdefekt entwickelte. Über ein Jahrzehnt später konnte dann erstmals ein Pyoderma gangraenosum diagnostiziert werden. Trotz einer konsequenten immunsuppressiven Therapie kam es zur weiteren Ausdehnung des Befunds. Unter der Anwendung einer Stammzelltherapie und dem Einsatz von Biologika verkleinert sich der Befund gegenwärtig langsam.
Abstract
Pyoderma gangrenosum is a rare autoinflammatory [1] neutrophil-rich dermatitis/panniculitis. We present a 59-year-old female patient who was treated for breast cancer and subsequently developed an extensive skin defect. More than ten years later pyoderma gangrenosum was diagnosed for the first time. Despite consistent immunosuppressive therapy, the findings were further extended. With the use of stem cell therapy and biologics, the findings are currently slowly decreasing.
Publication History
Article published online:
08 May 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Maverakis E, Marzano AV, Le ST. et al. Pyoderma gangrenosum. Nat Rev Dis Primers 2020; 6: 81 DOI: 10.1038/s41572-020-0213-x. (PMID: 33033263)
- 2 Maronese CA, Pimentel MA, Li MM. et al. Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments. Am J Clin Dermatol 2022; 23: 615-634 DOI: 10.1007/s40257-022-00699-8.
- 3 Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther 2013; 38: 563-572 DOI: 10.1111/apt.12431. (PMID: 23914999)
- 4 Wenzel J, Gerdsen R, Phillipp-Dormston W. et al. Topical treatment of pyoderma gangraenosum. Dermatology 2002; 205: 221-223 DOI: 10.1159/000065843.
- 5 Costa G, İlgün S, Pisani D. et al. A Rare Complication Following Breast Conserving Surgery: Pyoderma Gangrenosum. Eur J Breast Health 2023; 19: 331-334 DOI: 10.4274/ejbh.galenos.2023.2023-6-1.
- 6 Dissemond J, Marzano AV, Hampton PJ. et al. Pyoderma Gangrenosum: Treatment Options. Drugs 2023; 83: 1255-1267 DOI: 10.1007/s40265-023-01931-3. (PMID: 37610614)
- 7 Charles CA, Leon A, Banta MR. et al. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol 2007; 46: 1095-1099 DOI: 10.1111/j.1365-4632.2007.03286.x.
- 8 McPhie ML, Kirchhof MG. Pyoderma gangrenosum treated with secukinumab: A case report. SAGE Open Med Case Rep 2020; 8: 2050313X20940430 DOI: 10.1177/2050313X20940430. (PMID: 32733679)
- 9 Tee MW, Avarbock AB, Ungar J. et al. Rapid resolution of pyoderma gangrenosum with brodalumab therapy. JAAD Case Rep 2020; 6: 1167-1169 DOI: 10.1016/j.jdcr.2020.08.033.
- 10 Niebergall-Roth E, Frank NY, Ganss C. et al. Skin-derived ABCB5(+) mesenchymal stem cells for high-medical-need inflammatory diseases: From discovery to entering clinical routine. Int J Mol Sci 2022; 24: 66 DOI: 10.3390/ijms24010066.
- 11 RHEACELL GmbH & Co. KG. Technologie. 2023 Accessed December 19, 2023 at: https://www.rheacell.com/de/technologie/